We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Edan Instruments

EDAN Instruments manufactures and distributes diagnostic medical equipments in the areas of obstetrics & gynecology, ... read more Featured Products: More products

Download Mobile App

EDAN Takes its Solutions up a Notch at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022
Print article
Image: EDAN at MEDICA 2022 with its latest innovations (Photo courtesy of EDAN)
Image: EDAN at MEDICA 2022 with its latest innovations (Photo courtesy of EDAN)

EDAN Instruments, Inc. (Shenzhen, China) is demonstrating its range of latest innovations at MEDICA, the premiere global medical trade show being held at Dusseldorf, Germany, from Nov. 14 to 17, 2022. The company is presenting five new products to more than 120,000 visitors from over 150 countries at the world’s largest trade fair for the medical sector.

For the laboratory sector, EDAN is showcasing its combined range of POCT and IVD innovations at its booth this year, including the ClariLight CL30, its first molecular diagnostics solution. The ClariLight CL30 is a new point of care (POC) molecular diagnostics analysis system based on Loop-Mediated Isothermal Amplification (LAMP) that provides on-the-spot results and empowers physicians for early infectious disease diagnostics, thanks to its agility, speed and flexibility. ClariLight CL30 is designed to offer effective solutions for infectious disease diagnostics by reducing the window period. Unlike PCR-based methods (generally non-portable, laboratory setting, time-consuming), CL30 produces molecular results as quick as 15 minutes, while multi-parameters cartridges and the extraction-free procedure allow massive and rapid molecular tests feasible.

At MEDICA 2022, EDAN is also showcasing iX Series, its next-generation patient monitor that comes with a widescreen design and optimized workflow. Its innovative non-invasive technologies and selective clinical tools contribute to more efficient patient monitoring. Visitors to EDAN’s booth at MEDICA 2022 can experience two ready-to-launch products from the company, including the fully-automated electrocardiograph SE-1201 Pro, and the Holter ECG & ABP 2-in-1 wearables SA-20, tailored for the diagnosis of cardiogenic hypertension. In the obstetrics & gynecology area, EDAN is presenting its portable biofeedback and stimulation system, PA4 Pro, which allows physiotherapists to deliver pelvic floor muscular assessment and treatment flexibly in any scenario. For the first time, EDAN is also exhibiting the upgraded version of Acclarix LX9 alongside its technologically upgraded transducers.

"The highlight is our first molecular diagnostics solution, ClariLight CL30. We are glad to see that most clients are attracted by its rapid results as quick as 15 minutes," said Bo Wang, IVD & POCT Marketing Manager at EDAN.

"A rolling stone gathers no moss. Our breakthrough is visible," said Alex You, Senior Director of EDAN Global Marketing & Strategic Operations, after having a dialogue on EDAN's global development plan with Mr. Wolfram Nikolaus Diener, President & CEO of Messe Dusseldorf GmbH. "And we will go further with a steady stream to advance in our journey towards improving human living conditions."

Related Links:
EDAN Instruments, Inc.

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Rickettsia Conorii Assay

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.